Literature DB >> 27068955

Novel targets and interaction partners of mutant p53 Gain-Of-Function.

Lydia Aschauer1, Patricia A J Muller2.   

Abstract

In many human cancers p53 expression is lost or a mutant p53 protein is expressed. Over the past 15 years it has become apparent that a large number of these mutant p53 proteins have lost wild type function, but more importantly have gained functions that promote tumorigenesis and drive chemo-resistance, invasion and metastasis. Many researchers have investigated the underlying mechanisms of these Gain-Of-Functions (GOFs) and it has become apparent that many of these functions are the result of mutant p53 hijacking other transcription factors. In this review, we summarize the latest research on p53 GOF and categorize these in light of the hallmarks of cancer as presented by Hannahan and Weinberg.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  Gain-Of-Function; hallmarks of cancer; mutant p53

Mesh:

Substances:

Year:  2016        PMID: 27068955     DOI: 10.1042/BST20150261

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  25 in total

1.  APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.

Authors:  Yuheng Hong; Tianyuan Ren; Xiaoxuan Wang; Xia Liu; Yue Fei; Shen Meng; Xu Han; Cong Sun; Hongru Shen; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Huilai Zhang; Xianhuo Wang
Journal:  Leukemia       Date:  2022-07-14       Impact factor: 12.883

2.  Rab11-FIP1/RCP Functions as a Major Signalling Hub in the Oncogenic Roles of Mutant p53 in Cancer.

Authors:  Yannick von Grabowiecki; Vinaya Phatak; Lydia Aschauer; Patricia A J Muller
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 5.738

Review 3.  A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.

Authors:  Golap Babu; Shad Bin Islam; Md Asaduzzaman Khan
Journal:  Mol Biol Rep       Date:  2022-03-11       Impact factor: 2.742

Review 4.  Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.

Authors:  Russel J Reiter; Sergio A Rosales-Corral; Dun-Xian Tan; Dario Acuna-Castroviejo; Lilan Qin; Shun-Fa Yang; Kexin Xu
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

Review 5.  Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.

Authors:  Tzu-Ting Huang; Jung-Chen Su; Chun-Yu Liu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Int J Mol Sci       Date:  2017-06-08       Impact factor: 5.923

Review 6.  New therapeutic strategies to treat human cancers expressing mutant p53 proteins.

Authors:  Giovanni Blandino; Silvia Di Agostino
Journal:  J Exp Clin Cancer Res       Date:  2018-02-15

7.  The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells.

Authors:  Giovanna Butera; Jessica Brandi; Chiara Cavallini; Aldo Scarpa; Rita T Lawlor; Maria Teresa Scupoli; Emílio Marengo; Daniela Cecconi; Marcello Manfredi; Massimo Donadelli
Journal:  Biomolecules       Date:  2020-06-09

Review 8.  Putting p53 in Context.

Authors:  Edward R Kastenhuber; Scott W Lowe
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

9.  Genomic instability in mutant p53 cancer cells upon entotic engulfment.

Authors:  Hannah L Mackay; David Moore; Callum Hall; Nicolai J Birkbak; Mariam Jamal-Hanjani; Saadia A Karim; Vinaya M Phatak; Lucia Piñon; Jennifer P Morton; Charles Swanton; John Le Quesne; Patricia A J Muller
Journal:  Nat Commun       Date:  2018-08-03       Impact factor: 14.919

Review 10.  p53 Isoforms and Their Implications in Cancer.

Authors:  Maximilian Vieler; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2018-08-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.